JP2013508400A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508400A5
JP2013508400A5 JP2012535373A JP2012535373A JP2013508400A5 JP 2013508400 A5 JP2013508400 A5 JP 2013508400A5 JP 2012535373 A JP2012535373 A JP 2012535373A JP 2012535373 A JP2012535373 A JP 2012535373A JP 2013508400 A5 JP2013508400 A5 JP 2013508400A5
Authority
JP
Japan
Prior art keywords
composition
weeks
days
cancer
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012535373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508400A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/053579 external-priority patent/WO2011050180A1/en
Publication of JP2013508400A publication Critical patent/JP2013508400A/ja
Publication of JP2013508400A5 publication Critical patent/JP2013508400A5/ja
Withdrawn legal-status Critical Current

Links

JP2012535373A 2009-10-21 2010-10-21 新規な投与レジメンおよび治療法 Withdrawn JP2013508400A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25380409P 2009-10-21 2009-10-21
US61/253,804 2009-10-21
PCT/US2010/053579 WO2011050180A1 (en) 2009-10-21 2010-10-21 Novel dosing regimen and method of treatment

Publications (2)

Publication Number Publication Date
JP2013508400A JP2013508400A (ja) 2013-03-07
JP2013508400A5 true JP2013508400A5 (2) 2013-12-05

Family

ID=43898626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535373A Withdrawn JP2013508400A (ja) 2009-10-21 2010-10-21 新規な投与レジメンおよび治療法

Country Status (13)

Country Link
US (1) US20110097345A1 (2)
EP (1) EP2490715A4 (2)
JP (1) JP2013508400A (2)
KR (1) KR20120094472A (2)
CN (1) CN102630165A (2)
AU (1) AU2010310577A1 (2)
BR (1) BR112012009250A2 (2)
CA (1) CA2775806A1 (2)
IL (1) IL219279A0 (2)
IN (1) IN2012DN02826A (2)
MX (1) MX2012004406A (2)
RU (1) RU2012120691A (2)
WO (1) WO2011050180A1 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
RU2012131663A (ru) * 2010-01-21 2014-02-27 Иммьюноджен, Инк. Композиции и способы лечения рака яичников
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014052876A1 (en) * 2012-09-28 2014-04-03 Immunogen Inc. Methods for increasing efficacy of cd56- based therapy
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
SG11201509043RA (en) * 2013-05-14 2015-12-30 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
PL3055332T3 (pl) * 2013-10-08 2020-02-28 Immunogen, Inc. Schematy dawkowania immunokoniugatu anty-FOLR1
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
ES2972741T3 (es) * 2016-08-10 2024-06-14 Celgene Quanticel Res Inc Tratamiento del carcinoma de células de Merkel
MX2019005833A (es) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
MX2020013466A (es) * 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2021245238A1 (en) * 2020-06-04 2021-12-09 Bioinvent International Ab Improving antibody tolerability associated with intravenous administration
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN121152872A (zh) * 2023-05-10 2025-12-16 南京传奇生物科技有限公司 嵌合抗原受体及其使用方法
CN120173115A (zh) * 2025-05-20 2025-06-20 苏州欣协生物科技有限公司 一种抗人cd56蛋白工程抗体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU775373B2 (en) * 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1427377A4 (en) * 2001-09-20 2006-04-12 Cornell Res Foundation Inc METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISORDERS USING SPECIFIC BINDING AGENTS FOR A PROSTATE-SPECIFIC MEMBRANE ANTIGEN
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
CN1816356A (zh) * 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
JP2006526662A (ja) * 2003-06-05 2006-11-24 アシュカル,チャールズ 過増殖性細胞疾患を治療する方法
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
CA2727278A1 (en) * 2008-06-16 2010-01-21 Immunogen, Inc. Novel synergistic effects
RU2012131663A (ru) * 2010-01-21 2014-02-27 Иммьюноджен, Инк. Композиции и способы лечения рака яичников
US20120269827A1 (en) * 2011-04-01 2012-10-25 Immunogen, Inc. Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube Cancer

Similar Documents

Publication Publication Date Title
JP2013508400A5 (2)
Huang et al. Recent advances in CAR-T cell engineering
US20230115328A1 (en) Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
JP6877147B2 (ja) 放射線療法と併用されるpd−1およびpd−l1に対する拮抗薬を用いたがんの治療法
RU2012120691A (ru) Новый режим дозирования и способ лечения
BR112020022879A2 (pt) métodos e composições para tratamento de câncer
CN102711825A (zh) 用于施用EpCAMxCD3双特异性抗体的给药方案
van de Donk et al. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
KR20180100539A (ko) 치료용 조성물, 병용 및 적용과 관련된 사용방법
JP2009518441A5 (2)
JP2019503387A5 (2)
TW202220654A (zh) 用於治療癌症之組合
JP2014505056A5 (2)
CN118593691A (zh) 施用嵌合抗原受体免疫疗法的方法
Flinn et al. Recent advances in graft-versus-host disease
CN113939503A (zh) 激酶抑制剂的结晶盐形式
WO2019169015A1 (en) Anti cd6 antibodies for treating severe asthma
Sato et al. Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil
AU2022377644A1 (en) Anti-ctla-4 antibody dosing regimens
WO2023034864A1 (en) Compositions and methods for treating cancers
Creber et al. Current and emerging approaches to cochlear immunosuppression with translation to human inner ear stem cell therapy: A systematic review
WO2022109299A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US20240342195A1 (en) Agent for combination use comprising t cell and/or b cell activity regulator
JP2014508809A5 (2)
Durmaz et al. Overview of current approaches in cancer immunotherapy and personalized opportunities for future aspect